Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12,545 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ectopic Breast Cancer Arising within an Axillary Lymph Node.
Toshima K, Shien T, Nishimura MF, Suzuki Y, Nakamoto S, Uno M, Yoshioka R, Tsukioki T, Takahashi Y, Iwamoto T, Iwatani T, Yanai H. Toshima K, et al. Among authors: takahashi y. Acta Med Okayama. 2024 Feb;78(1):89-93. doi: 10.18926/AMO/66676. Acta Med Okayama. 2024. PMID: 38419320 Free article.
The efficacy and feasibility of dose-dense sequential chemotherapy for Japanese patients with breast cancer.
Takabatake D, Kajiwara Y, Ohtani S, Itano Y, Yamamoto M, Kubo S, Ikeda M, Takahashi M, Hara F, Aogi K, Ohsumi S, Ogasawara Y, Nishiyama Y, Hikino H, Matsuoka K, Takahashi Y, Shien T, Taira N, Doihara H. Takabatake D, et al. Among authors: takahashi m, takahashi y. Breast Cancer. 2018 Nov;25(6):717-722. doi: 10.1007/s12282-018-0877-1. Epub 2018 Jun 11. Breast Cancer. 2018. PMID: 29948957 Clinical Trial.
Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer.
Takahashi Y, Iwamoto T, Suzuki Y, Kajiwara Y, Hatono M, Tsukioki T, Kawada K, Kochi M, Ikeda H, Shien T, Taira N, Matsuoka J, Doihara H, Toyooka S. Takahashi Y, et al. Clin Breast Cancer. 2020 Apr;20(2):117-124.e4. doi: 10.1016/j.clbc.2019.07.001. Epub 2019 Sep 9. Clin Breast Cancer. 2020. PMID: 31570267 Free article.
YES1 as a Therapeutic Target for HER2-Positive Breast Cancer after Trastuzumab and Trastuzumab-Emtansine (T-DM1) Resistance Development.
Fujihara M, Shien T, Shien K, Suzawa K, Takeda T, Zhu Y, Mamori T, Otani Y, Yoshioka R, Uno M, Suzuki Y, Abe Y, Hatono M, Tsukioki T, Takahashi Y, Kochi M, Iwamoto T, Taira N, Doihara H, Toyooka S. Fujihara M, et al. Among authors: takahashi y. Int J Mol Sci. 2021 Nov 26;22(23):12809. doi: 10.3390/ijms222312809. Int J Mol Sci. 2021. PMID: 34884609 Free PMC article.
Development and validation of a symptom illustration scale from the patient-reported outcome common terminology criteria for adverse events for patients with breast cancer.
Suzuki Y, Iwamoto T, Uno M, Hatono M, Kajiwara Y, Takahashi Y, Kochi M, Shien T, Kikawa Y, Uemura Y, Hagiwara Y, Yamamoto S, Taira N, Doihara H, Toyooka S. Suzuki Y, et al. Among authors: takahashi y. Breast Cancer. 2023 Sep;30(5):856-868. doi: 10.1007/s12282-023-01480-3. Epub 2023 Jul 8. Breast Cancer. 2023. PMID: 37422608
12,545 results
You have reached the last available page of results. Please see the User Guide for more information.